975 related articles for article (PubMed ID: 17330072)
21. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
Sudhakar Y; Kuotsu K; Bandyopadhyay AK
J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
[TBL] [Abstract][Full Text] [Related]
22. Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
Müller CE
Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841
[TBL] [Abstract][Full Text] [Related]
23. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
[TBL] [Abstract][Full Text] [Related]
24. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
Cole ET; Cadé D; Benameur H
Adv Drug Deliv Rev; 2008 Mar; 60(6):747-56. PubMed ID: 18096270
[TBL] [Abstract][Full Text] [Related]
25. Enhancing oral absorption in animals.
Crowley PJ; Martini LG
Curr Opin Drug Discov Devel; 2001 Jan; 4(1):73-80. PubMed ID: 11727326
[TBL] [Abstract][Full Text] [Related]
26. In vitro digestion kinetics of excipients for lipid-based drug delivery and introduction of a relative lipolysis half life.
Arnold YE; Imanidis G; Kuentz M
Drug Dev Ind Pharm; 2012 Oct; 38(10):1262-9. PubMed ID: 22206451
[TBL] [Abstract][Full Text] [Related]
27. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.
Cherniakov I; Izgelov D; Domb AJ; Hoffman A
Eur J Pharm Sci; 2017 Nov; 109():21-30. PubMed ID: 28736128
[TBL] [Abstract][Full Text] [Related]
28. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.
Fahr A; van Hoogevest P; May S; Bergstrand N; S Leigh ML
Eur J Pharm Sci; 2005 Nov; 26(3-4):251-65. PubMed ID: 16112849
[TBL] [Abstract][Full Text] [Related]
29. Complex Interplay Between Solubilization, Digestion, Supersaturation and Absorption of Poorly Soluble Drugs with Lipid-Based Formulations.
Jannin V
Curr Drug Deliv; 2018; 15(6):749-751. PubMed ID: 29046150
[No Abstract] [Full Text] [Related]
30. [Oral bioavailability and drug/carrier particulate systems].
Wawrezinieck A; Péan JM; Wüthrich P; Benoit JP
Med Sci (Paris); 2008; 24(6-7):659-64. PubMed ID: 18601886
[TBL] [Abstract][Full Text] [Related]
31. Oral colon delivery: rationale and time-based drug design strategy.
Gazzaniga A; Maroni A; Foppoli A; Palugan L
Discov Med; 2006 Dec; 6(36):223-8. PubMed ID: 17250787
[TBL] [Abstract][Full Text] [Related]
32. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
Pouton CW
Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
[TBL] [Abstract][Full Text] [Related]
33. Lipid-Based Formulations for Oral Drug Delivery: Effects on Drug Absorption and Metabolism.
Zhu Q; Li X; Xia D; Yu H; Chen D; Fan W; Gan Y
Curr Drug Metab; 2015; 16(3):200-10. PubMed ID: 26279327
[TBL] [Abstract][Full Text] [Related]
34. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
35. The utility of cyclodextrins for enhancing oral bioavailability.
Carrier RL; Miller LA; Ahmed I
J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
[TBL] [Abstract][Full Text] [Related]
36. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.
Trevaskis NL; Charman WN; Porter CJ
Adv Drug Deliv Rev; 2008 Mar; 60(6):702-16. PubMed ID: 18155316
[TBL] [Abstract][Full Text] [Related]
37. 50years of oral lipid-based formulations: Provenance, progress and future perspectives.
Feeney OM; Crum MF; McEvoy CL; Trevaskis NL; Williams HD; Pouton CW; Charman WN; Bergström CAS; Porter CJH
Adv Drug Deliv Rev; 2016 Jun; 101():167-194. PubMed ID: 27089810
[TBL] [Abstract][Full Text] [Related]
38. Armamentarium of nanoscaled lipid drug delivery systems customized for oral administration: In silico docking patronage, absorption phenomenon, preclinical status, clinical status and future prospects.
Baldi A; Chaudhary M; Sethi S; Abhiav ; Chandra R; Madan J
Colloids Surf B Biointerfaces; 2018 Oct; 170():637-647. PubMed ID: 29986259
[TBL] [Abstract][Full Text] [Related]
39. Estimating drug solubility in the gastrointestinal tract.
Dressman JB; Vertzoni M; Goumas K; Reppas C
Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
[TBL] [Abstract][Full Text] [Related]
40. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.
Williams HD; Ford L; Han S; Tangso KJ; Lim S; Shackleford DM; Vodak DT; Benameur H; Pouton CW; Scammells PJ; Porter CJH
Mol Pharm; 2018 Dec; 15(12):5678-5696. PubMed ID: 30376336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
